Morning Edition · №
Medicine SYDNEY

A Rare Fever Disorder Reveals a 30-Year-Old Misunderstanding About the Immune System

Researchers found that a dangerous inflammatory disease long blamed on one type of immune cell is actually driven by a different one that fails to kill infected cells properly.

SHARE X f in ⧉

Scientists at Australia's Garvan Institute of Medical Research say they have overturned three decades of thinking about what drives a rare and sometimes life-threatening inflammatory disorder, a discovery that points to an existing arthritis drug as a possible new treatment.

The condition, mevalonate kinase deficiency, or MKD, causes recurring attacks of high fever, skin rashes, joint pain and abdominal inflammation that can turn life-threatening in severe cases. For roughly three decades, research into the disease has focused on macrophages, immune cells that coordinate the body's inflammatory response, and existing treatments work by blocking a signal those cells release. But about half of patients do not respond adequately to that approach.

The real culprit: cells that can't finish the job

Examining blood samples from MKD patients and preclinical models, the Garvan team found that natural killer cells — which normally destroy virus-infected cells — are themselves defective in people with the disorder. "We found that these immune cells are essentially misfiring," said Professor Mike Rogers, the study's senior author. "NK cells are loaded with toxic ammunition, stored in granules that are released to kill infected cells. However, in MKD these toxic granules can't be released from NK cells and remain trapped inside. When an NK cell fails to kill its target, it compensates by shouting for help, pumping out large amounts of interferon gamma — a powerful inflammatory signal. This activates other immune cells and causes the dangerous fever and widespread inflammation seen in patients."

"This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease," said Dr Marcia Munoz, the study's lead researcher. "In MKD, the primary problem is in NK cells and not in macrophages, as previously believed."

An existing drug, tried on one infant

Working with doctors at the Royal Children's Hospital in Melbourne, the researchers tested baricitinib — a JAK inhibitor already used for rheumatoid arthritis and eczema — on a severely affected infant whose standard treatment wasn't working. Inflammatory flare-ups became less frequent and severe gastrointestinal inflammation began to heal after the drug was added to the child's regimen. The researchers caution that a single case cannot prove the treatment works more broadly, and the findings, published in the journal Immunity, will need to be tested in formal clinical trials. The team has also proposed the term "prenylopathies" for a wider family of genetic disorders that share the same affected metabolic pathway, raising the possibility that NK-cell dysfunction could explain more than one disease at once.

SHARE THIS ARTICLE X Facebook LinkedIn Copy link
Samuel Okafor · Health & Medicine Correspondent

Covers health and medicine for UBStandard: drug approvals, clinical research and the systems that deliver care.

[email protected]
Related coverage Front page →